Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Sebela Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Tegoprazan (CJ-12420) is a novel agent in development for the treatment of acid-related gastrointestinal diseases. Tegoprazan has already received marketing authorization in multiple territories, including South Korea and China.
Brand Name : CJ-12420
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 19, 2022
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Sebela Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?